SCHEMBL22200531

SCHEMBL22200531

CC(C)n1c(=O)c(-c2ccc(NSCCC(C)(F)F)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.42
MTOR P42345 5/20 0.35
CYP1A2 P05177 8/20 0.35
CYP3A4 P08684 7/20 0.35
USP2 O75604 6/20 0.35
HSD17B10 Q99714 3/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 4/20 0.35
BRAF P15056 1/20 0.33
RORC P51449 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HIF1A Q16665 1/20 0.32
CYP2C9 P11712 3/20 0.32
CYP2C19 P33261 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200355 0.94 ERN1 (0.41) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL22200546 0.90 ERN1 (0.42) ERN1CYP1A2CYP3A4USP2HSD17B10
SCHEMBL22200356 0.90 ERN1 (0.41) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL22200563 0.89 ERN1 (0.46) ERN1CYP1A2CYP3A4USP2HSD17B10
SCHEMBL22200353 0.88 ERN1 (0.40) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL22200553 0.87 ERN1 (0.40) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL25035267 0.86 ERN1 (0.49) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL22200626 0.86 ERN1 (0.41) ERN1MTORBRAFPIK3CA
SCHEMBL22200790 0.86 ERN1 (0.42) ERN1MTORCYP1A2CYP3A4USP2
SCHEMBL22200817 0.86 MTOR (0.40) ERN1MTORCYP1A2CYP3A4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed